Posted inBiotechnology
Posted inBiotechnology
Idorsia’s sale of Tryvio falls behind schedule, but layoffs remain on track
Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump, even as the biotech ploughs ahead with around…

















